The Filing Desk

AtriCure vs Bioventus

AtriCure ATRC · Bioventus BVS · Health Care Equipment

Bioventus reported revenue of $568 million in fiscal 2025, about the same as AtriCure's $534 million in fiscal 2025. AtriCure's revenue grew 14.9% in its latest year, and Bioventus' fell 0.9%. AtriCure had an operating margin of -1.8%, against 9.5% at Bioventus. Free cash flow was $48 million at AtriCure and $72 million at Bioventus.

Side by side

AtriCureBioventus
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$534M$568M
Revenue growth14.9%−0.9%
Revenue growth a year, last 5 years20.9%12.1%
Gross margin75.0%68.3%
Operating margin−1.8%9.5%
Net margin−2.1%4.0%
Free cash flow$48M$72M
Free cash flow margin9.0%12.7%
Return on capital−1.9%11.1%
Net debt to EBITDA−8.9x2.5x
Dividends and buybacks$0M$0M
Change in diluted share count1.7%6.8%
Last close$56.84$10.66
P/E at the last close189.5×13.3×
Insider trades, last 12 monthssold $4.4 million—
Piotroski F-score7 of 98 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
AtriCureBioventus
Operating margin
Percent of revenue
AtriCureBioventus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AtriCureBioventus

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the AtriCure and Bioventus pages.